Array BioPharma

Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch

Retrieved on: 
Monday, October 23, 2023
FDA, HCC, Greater China, PDUFA, Food, Strategic planning, Incyte, Kutztown University of Pennsylvania, University, Mesothelioma, Bowling Green State University, Regulation of tobacco by the U.S. Food and Drug Administration, Pfizer, Array BioPharma, Cunningham, Business administration, Hepatocellular carcinoma, Football, Therapy, Master of Business Administration, Patient, Communication, Pharmaceutical industry, Management

"The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.

Key Points: 
  • "The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.
  • “Both possess a wealth of sales and management acumen, and a great understanding of the road ahead for our company.
  • Cunningham joins Elevar from global oncology company Novocure, where he served as the national sales and operations lead for its Central Nervous System Cancers Franchise.
  • He was previously vice president of sales for rare commercial services at Dohmen Life Science Services, and director of Eisai Inc.’s government payer team.

Think Bioscience Expands Leadership Team in Drug Discovery with Key Additions

Retrieved on: 
Thursday, November 10, 2022
CO, GLOBE, Pfizer, Translation, Synthetic biology, Drug discovery, Icos, Therapy, Medicinal chemistry, Science Advisory Board, VP-Info, Genentech, Microbiology, Coronavirus Scientific Advisory Board (Turkey), Array BioPharma, CU, Patient, CEO, VP, Acquisition, Pharmaceutical industry, Chemistry, University of Colorado Boulder

Allen brings over 20 years of drug discovery successes in Colorado including at Array Biopharma and subsequently with Pfizer.

Key Points: 
  • Allen brings over 20 years of drug discovery successes in Colorado including at Array Biopharma and subsequently with Pfizer.
  • We are thrilled to welcome Shelley Allen and her rich experience to our growing team, said Jerome Fox, co-founder and CEO at Think Bioscience.
  • I am delighted to work with the Think team as they continue their focus on drug discovery.
  • The unique approach to drug discovery combines applied microbiology, enzymology, and computational science to develop small-molecule therapeutics against elusive targets.

AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs

Retrieved on: 
Wednesday, October 19, 2022
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, University of California, San Diego, Doctor of Philosophy, Leukemia, EGFR, Therapy, PARP, Development, Baxalta, Western Colorado University, VP, Array BioPharma, Strategic planning, ARIAD Pharmaceuticals, Takeda, Patient, Drug development, Research, Multimedia, Precision medicine, Degenerative disease, Cancer, University, Physiology, Lung cancer, Company, Drug discovery, NSCLC, Department, DRS, University of Colorado Denver, AXL, ROS1, Global Medical Device Nomenclature, Clinical research, Bayer, BeiGene, Record, Takeda Oncology, Developmental Biology (journal), University of Texas Health Science Center at San Antonio, TKI, Large-cell lung carcinoma, Pharmaceutical industry, Chemistry, Biology

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced the appointments of Heinrich Farin, M.D.

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced the appointments of Heinrich Farin, M.D.
  • as Senior Medical Director, Clinical Research and Michael J. Humphries, Ph.D., as VP, Head of US Medical Affairs.
  • View the full release here: https://www.businesswire.com/news/home/20221019005297/en/
    Michael J. Humphries, Ph.D., VP, Head of US Medical Affairs, AnHeart Therapeutics (Photo: Business Wire)
    Were delighted to welcome Drs.
  • AnHeart Therapeutics (AnHeart) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel or next-generation precision oncology therapeutics with high unmet medical needs.

Zephyr AI Appoints Allen Hodge as Chief Commercial Officer

Retrieved on: 
Tuesday, August 16, 2022
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Hematology, Precision medicine, Encorafenib, Drug discovery, CEO, Senior, Algorithm, ViroPharma, Growth, Cancer, Leadership, BioCryst Pharmaceuticals, Zephyr, Research, Pfizer, Marketing, Patient, Instagram, Twitter, Sutro Biopharma, Shire (pharmaceutical company), Hodge, Array BioPharma, Red Cell, BRAF, Diabetes, Hereditary angioedema, Solution, LinkedIn, Celgene, Organization, Pharmaceutical industry, Medical device, United, Berotralstat

Zephyr AI, Inc. (Zephyr AI), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer.

Key Points: 
  • Zephyr AI, Inc. (Zephyr AI), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer.
  • At Zephyr AI, Hodge provides senior leadership and strategic vision to support the companys commercial efforts.
  • The Zephyr AI team is poised to transform the way that the healthcare industry approaches drug discovery, development, and predictive analytics, said Hodge, Chief Commercial Officer of Zephyr AI.
  • As we enter into our next phase of evolution and growth as a company, it is incredibly exciting to welcome Allen to the Zephyr AI team, said David L. Morgan II, CEO of Zephyr AI.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Board of directors, Board, Commercial Operating System (COS), Pharmacokinetics, Secondary research, PMV, Research, BRAF, COVID-19, Chief commercial officer, Company, Cranbury, Breast cancer, Clinical trial, Corporation, Private Securities Litigation Reform Act, Safety, G&A, CMC, Cancer, Protein, Array BioPharma, Senior, DNA, Pfizer, Leadership, R, Nasdaq, Patient, Doctor of Philosophy, SEC, Renal cell carcinoma, Medical imaging, Pharmaceutical industry, Fine chemical

Fourth Quarter 2021 and Corporate Highlights:

Key Points: 
  • Fourth Quarter 2021 and Corporate Highlights:
    Patient enrollment in the Phase 1 portion of the Phase 1/2 clinical trial of PC14586 continues in line with the Companys expectations.
  • The Company plans to disclose initial results from this study in the first half of 2022.
  • In addition to continuing work on its p53 mutant programs, PMV expands its pipeline by advancing WIP1 (Wild-Type p53-Induced Phosphatase) inhibitor program, into lead optimization.
  • PMV Pharma ended the fourth quarter with$314.1 millionin cash, cash equivalents, and marketable securities, compared to$361.4 millionas ofDecember 31, 2020.

PMV Pharma Announces Changes to its Board of Directors

Retrieved on: 
Thursday, January 6, 2022
Harvard Business School, University, Psychology, Clinical trial, COVID-19, Procter, Large-cell lung carcinoma, List of Breaking Bad and Better Call Saul characters, Acquisition, Commercial Operating System (COS), Growth, Therapy, Procter & Gamble, Company, Patient, Cancer, Breast, Array BioPharma, U.S. Securities and Exchange Commission, Pfizer, Security (finance), Breast cancer, Private Securities Litigation Reform Act, IPO, MBA, SEC, Neoplasm, Â, SVP, Chief commercial officer, Board, GLOBE, Board of directors, Nasdaq, PMV, Leadership, Pharmaceutical industry, Management, Fine chemical, Medical imaging, Array, Science

"Kirsten is a talented leader with an impressive track record in product launches and commercial strategy, said Dr. Mack.

Key Points: 
  • "Kirsten is a talented leader with an impressive track record in product launches and commercial strategy, said Dr. Mack.
  • Flowers said, PMV is pioneering a differentiated approach to precision oncology with tumor agnostic small molecules targeting p53.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

ReForm Biologics Bolsters Diversity With New Appointments to Board of Directors

Retrieved on: 
Tuesday, September 21, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Technology, Other Technology, ACT, Technology, Biotechnology, Beacon Building Products, Harvard University, Cornell University, Commercial Operating System (COS), GID, Reform, Advanced Technology Ventures, MIT, Array, Baxter International, Economics, Stuart, Investment, BECN, BRAF, Patient, Psychology, Board, Division, Breast cancer, CEO, Jonathan Rothberg, University, Array BioPharma, Growth, Harvard Business School, McKinsey & Company, TFX, Pfizer, IPO, MBA, MPP, Safety, Bryant University, Renal cell carcinoma, Viscosity, SVP, BS, Accounting, Pharmaceutical industry, Management

A Board of Directors should reflect a company's mission, vision, and stage of development.

Key Points: 
  • A Board of Directors should reflect a company's mission, vision, and stage of development.
  • This is a crucial time in the evolution of ReForm and we are grateful to be able to benefit from the experience and insights of these new Directors.
  • Roopom Banerjee has over 25 years of experience in corporate strategy, investment banking, private equity, company formation and operating leadership.
  • Roopom is currently the Managing Partner of WhiteLeaf Advisors, a Strategic Advisor to Bain Capital, and an Operating Partner at CRG Investments.

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Retrieved on: 
Tuesday, September 14, 2021
Â, Alpha-synuclein, PD, Gaucher's disease, Patient, Gene, Eli Lilly, Rheumatoid arthritis, Department, Lists of diseases, Amyotrophic lateral sclerosis, Neurology, GD, Neurodegeneration, Genetics, University of Texas Southwestern Medical Center, GBA, Therapy, GLOBE, ALS, Diagnosis, AD, Cell, Neuron, Protein, Research, Series, Lymphatic system, Hope, Drug discovery, AbbVie, Calico (company), University, Drug development, Technology, Doctor of Philosophy, Company, Risk, Hepatitis C, Disease, Array BioPharma, GBA1, Pharmaceutical industry, Fine chemical

CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that it closed an $85 million Series B financing round, led by Omega Funds. The syndicate includes Series A investor OrbiMed and new investors Omega Funds, Surveyor Capital (a Citadel company), Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, and Osage University Partners. Proceeds from the financing will be used to accelerate the development of the company’s innovative therapeutic programs. The need for effective neurodegenerative therapies is urgent; every day, the lives of thousands of people are changed forever following a diagnosis of Parkinson’s disease (PD), Gaucher disease (GD), Alzheimer’s disease (AD), or amyotrophic lateral sclerosis (ALS).

Key Points: 
  • CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that it closed an $85 million Series B financing round, led by Omega Funds.
  • Vanqua Bio is helping usher in a new era of hope for people living with neurodegenerative disorders.
  • Vanqua Bios Series B financing will advance the companys best-in-class GCase activators into human testing within the next two years, initially focusing on GD and GBA-PD.
  • Co-Founder Dr. Dimitri Krainc , a leading expert on uncovering molecular pathways that contribute to neurodegenerative diseases, chairs Vanqua Bios Scientific Advisory Board.

ASLAN Pharmaceuticals to Present at 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Monday, February 24, 2020
Companies, Life sciences, Industries, Bristol-Myers Squibb, Almirall, Array BioPharma

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative product candidates that target significant unmet medical needs and global market opportunities.

Key Points: 
  • ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative product candidates that target significant unmet medical needs and global market opportunities.
  • ASLANs partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL.
  • These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company").
  • 001-38475), including the Companys Annual Report on Form 20-F for the year ended December 31, 2018 filed with the US Securities and Exchange Commission on April 29, 2019.

Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

Retrieved on: 
Monday, January 6, 2020
Companies, Life sciences, Array BioPharma, Pfizer, Economy of the United States

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer.

Key Points: 
  • SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer.
  • Flowers joins Kura most recently from Array Biopharma, where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfizer in July 2019.
  • Kirsten is a world-class leader in building successful commercial organizations and launching precision medicines for the treatment of cancer, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • Flowers brings extensive commercial experience leading top-performing oncology product launches at large pharmaceutical and biotechnology organizations.